Total Payments
$99,161
2024 Payments
$3,712
Companies
23
Transactions
194
Medicare Patients
11,808
Medicare Billing
$11.9M
Payment Breakdown by Category
Consulting$58,570 (59.1%)
Other$19,325 (19.5%)
Research$11,937 (12.0%)
Food & Beverage$6,175 (6.2%)
Travel$2,960 (3.0%)
Education$194.79 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $58,570 | 24 | 59.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,325 | 7 | 19.5% |
| Unspecified | $11,937 | 5 | 12.0% |
| Food and Beverage | $6,175 | 148 | 6.2% |
| Travel and Lodging | $2,960 | 8 | 3.0% |
| Education | $194.79 | 2 | 0.2% |
Payments by Type
General
$87,224
189 transactions
Research
$11,937
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $27,557 | 32 | $0 (2024) |
| F. Hoffmann-La Roche AG | $18,172 | 8 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $15,579 | 39 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $14,565 | 14 | $0 (2021) |
| Genentech, Inc. | $14,112 | 22 | $0 (2023) |
| Alcon Research LLC | $3,850 | 1 | $0 (2023) |
| Alimera Sciences, Inc. | $2,881 | 15 | $0 (2024) |
| Allergan Inc. | $677.15 | 7 | $0 (2019) |
| Otsuka America Pharmaceutical, Inc. | $454.94 | 23 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $374.39 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,712 | 27 | F. Hoffmann-La Roche AG ($2,623) |
| 2023 | $6,944 | 28 | Alcon Research LLC ($3,850) |
| 2022 | $22,345 | 47 | Genentech USA, Inc. ($14,153) |
| 2021 | $14,200 | 11 | Regeneron Healthcare Solutions, Inc. ($4,860) |
| 2020 | $18,647 | 12 | Novartis Pharmaceuticals Corporation ($7,187) |
| 2019 | $20,817 | 27 | Genentech USA, Inc. ($13,084) |
| 2018 | $8,482 | 23 | Genentech, Inc. ($5,958) |
| 2017 | $4,014 | 19 | Alimera Sciences, Inc. ($2,652) |
All Payment Transactions
194 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $26.73 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $0.84 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/31/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $30.74 | General |
| Category: Ophthalmology | ||||||
| 10/17/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $180.48 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/17/2024 | Carl Zeiss Meditec USA, Inc. | CIRRUS HD-OCT (Device) | Food and Beverage | In-kind items and services | $153.13 | General |
| Category: Optical Tomography | ||||||
| 10/10/2024 | Genentech USA, Inc. | Susvimo (Drug), Vabysmo | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/04/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/18/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 08/29/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: EYE CARE | ||||||
| 07/18/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $29.30 | General |
| Category: Ophthalmology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $2,623.08 | Research |
| Study: STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: Ophthalmology | ||||||
| 06/27/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: Ophthalmology | ||||||
| 05/16/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/09/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: Ophthalmology | ||||||
| 05/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $89.09 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/25/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: PSYCHIATRY | ||||||
| 04/22/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: EYE CARE | ||||||
| 04/18/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 04/15/2024 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $126.36 | General |
| 03/07/2024 | Alcon Vision LLC | HYDRUS Microstent (Device) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: Ophthalmology | ||||||
| 03/04/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Education | In-kind items and services | $99.99 | General |
| Category: IMMUNOLOGY | ||||||
| 03/04/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: EYE CARE | ||||||
| 02/22/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: Immunology and Ophthalmology | ||||||
| 02/02/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $23.42 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE II MULTICENTER, RANDOMIZED, ACTIVE TREATMENT-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | F. Hoffmann-La Roche AG | $5,924 | 2 |
| PDS PHASE 3 ARCHWAY | F. Hoffmann-La Roche AG | $2,765 | 1 |
| STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | F. Hoffmann-La Roche AG | $2,623 | 1 |
| A PHASE III, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED, ACTIVE COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA PAGODA | F. Hoffmann-La Roche AG | $625.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,446 | 20,842 | $11.2M | $2.4M |
| 2022 | 24 | 3,000 | 17,247 | $15.1M | $3.0M |
| 2021 | 16 | 3,204 | 13,726 | $17.3M | $3.3M |
| 2020 | 17 | 3,158 | 12,261 | $9.0M | $3.2M |
Total Patients
11,808
Total Services
64,076
Medicare Billing
$11.9M
Procedure Codes
74
All Medicare Procedures & Services
74 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 224 | 2,178 | $8.2M | $1.5M | 18.2% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 25 | 11,040 | $441,600 | $321,411 | 72.8% |
| J2779 | Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg | Office | 2023 | 13 | 2,400 | $216,000 | $153,387 | 71.0% |
| 67028 | Injection of drug into eye | Office | 2023 | 456 | 1,591 | $799,751 | $146,625 | 18.3% |
| J3490 | Unclassified drugs | Office | 2023 | 32 | 56 | $130,813 | $97,286 | 74.4% |
| 92134 | Imaging of retina | Office | 2023 | 737 | 1,926 | $304,192 | $54,412 | 17.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 12 | 229 | $318,108 | $42,186 | 13.3% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 31 | 33 | $148,566 | $27,295 | 18.4% |
| J3590 | Unclassified biologics | Office | 2023 | 155 | 548 | $175,827 | $27,190 | 15.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 296 | 325 | $158,275 | $25,353 | 16.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 198 | 220 | $111,320 | $18,023 | 16.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 136 | 164 | $58,384 | $9,975 | 17.1% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 31 | 32 | $14,240 | $3,160 | 22.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $17,108 | $2,930 | 17.1% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Facility | 2023 | 13 | 13 | $26,169 | $2,911 | 11.1% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 30 | 30 | $17,400 | $2,861 | 16.4% |
| 92250 | Photography of the retina | Office | 2023 | 31 | 31 | $4,681 | $668.80 | 14.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 249 | 2,824 | $10.7M | $2.0M | 18.9% |
| J3490 | Unclassified drugs | Office | 2022 | 29 | 118 | $833,000 | $215,835 | 25.9% |
| 67028 | Injection of drug into eye | Office | 2022 | 456 | 2,170 | $1.1M | $198,733 | 18.4% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 28 | 3,960 | $158,400 | $118,172 | 74.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 13 | 383 | $532,025 | $85,699 | 16.1% |
| 92134 | Imaging of retina | Office | 2022 | 849 | 2,700 | $426,152 | $77,134 | 18.1% |
| J2779 | Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg | Office | 2022 | 11 | 1,200 | $108,000 | $77,006 | 71.3% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2022 | 44 | 47 | $211,594 | $41,647 | 19.7% |
About Dr. Daniel Miller, MD
Dr. Daniel Miller, MD is a Ophthalmology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487681987.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Miller, MD has received a total of $99,161 in payments from pharmaceutical and medical device companies, with $3,712 received in 2024. These payments were reported across 194 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($58,570).
As a Medicare-enrolled provider, Miller has provided services to 11,808 Medicare beneficiaries, totaling 64,076 services with total Medicare billing of $11.9M. Data is available for 4 years (2020–2023), covering 74 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Cincinnati, OH
- Active Since 06/28/2006
- Last Updated 12/18/2007
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1487681987
Products in Payments
- Lucentis (Biological) $40,385
- EYLEA (Biological) $14,771
- BEOVU (Drug) $14,376
- Iluvien (Drug) $2,719
- SUSVIMO (Drug) $2,040
- Non-Covered Product (Drug) $753.91
- OZURDEX (Drug) $655.86
- EYLEA AFLIBERCEPT INJECTION (Biological) $552.92
- REXULTI (Drug) $434.39
- EYLEA HD (Biological) $297.14
- VABYSMO (Drug) $242.86
- CIRRUS HD-OCT (Device) $153.13
- Vabysmo (Drug) $150.31
- YUTIQ (Drug) $145.62
- Syfovre (Drug) $121.14
- XEN (Device) $108.51
- ACTHAR (Biological) $99.99
- ILUVIEN (Drug) $76.92
- Izervay (Drug) $51.28
- XARELTO (Drug) $48.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Cincinnati
Dr. Robert Osher, Md, MD
Ophthalmology — Payments: $1.2M
Ophthalmology $1.2M
Dr. Christopher Riemann, M.d, M.D
Ophthalmology — Payments: $750,272
Ophthalmology $750,272
Dr. Anup Khatana, Md, MD
Ophthalmology — Payments: $418,163
Ophthalmology $418,163
Dr. Michael Snyder, M.d, M.D
Ophthalmology — Payments: $344,869
Ophthalmology $344,869
Dr. Hisham Arar, Md, MD
Ophthalmology — Payments: $79,380
Ophthalmology $79,380
Dr. Michael Nordlund, Md, MD
Ophthalmology — Payments: $59,099
Ophthalmology $59,099